Condition: Mild Cognitive Impairment (MCI) · Sponsor: Pravat Mandal
The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.
This description comes directly from the study's public registry record.
Pravat Pravat K MANDAL · 4126999561 · mandalpk@pitt.edu
Nazia Pillar · 878-670-3123 · clinic55@pitt.edu
Always discuss trial participation with your own doctor first.
| UPMC Presbyterian Hospital | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07583251